Gongxin-KY Accelerates Global Expansion for Lung Cancer Drug; Expects Growth in China
Gongxin-KY expects growth in the second half of the year following sales strategy optimization for its lung cancer drug PTS302 in China, while accelerating international licensing.
📋 Article Processing Timeline
- 📰 Published: May 26, 2026 at 20:00
- 🔍 Collected: May 26, 2026 at 20:31 (31 min after Published)
- 🤖 AI Analyzed: May 31, 2026 at 19:46 (119h 14m after Collected)
Taipei, May 26 (CNA) - Lin Mao-yuan, General Manager of drug developer Gongxin-KY, stated that the company expects growth momentum in the second half of the year following the optimization of sales strategies for its lung cancer drug, PTS302, in China. PTS302 is accelerating international licensing, with new drug applications (NDA) submitted in multiple countries. During an investor conference today, Lin noted that the company is completing Phase II clinical trials for its liver cancer drug, PTS100, and is nearing approval for a pet cancer drug. Cumulative revenue for the first four months of this year reached NT$12.86 million, a 15.9% year-on-year increase.
FAQ
What is the new drug?
PTS302 for lung cancer.